Your colleague is treating a pregnant diabetic patient and seeks your opinion on her treatment regimen. Before speaking with your colleague, you know the preferred treatment option for pregnant diabetic patients is which following:

Rationale: A. Insulin is the preferred pharmacological agent for managing diabetes during pregnancy because it does not cross the placenta in significant amounts. Rapid acting analogs like Insulin Lispro allow for precise postprandial glucose control, which is essential to prevent fetal macrosomia and neonatal hypoglycemia. It provides the most reliable efficacy and safety profile for both the mother and the developing fetus. B. SGLT-2 inhibitors are generally avoided during pregnancy due to potential risks to fetal renal development observed in animal studies. These medications alter renal physiology and glucose excretion, which could negatively impact the delicate fluid and electrolyte balance required for a healthy pregnancy. There is currently insufficient clinical data to support their safety in the human obstetric population. C. While lifestyle modifications such as medical nutrition therapy are the first step, many pregnant patients require medication to meet strict glycemic targets. Relying solely on lifestyle when targets are not met increases the risk of preeclampsia and adverse neonatal outcomes. Pharmacological intervention is indicated whenever blood glucose levels exceed the recommended thresholds to ensure a safe gestational environment. D. Meglitinides like repaglinide are secretagogues that stimulate insulin release but are not considered first-line therapy in pregnancy. Most oral hypoglycemic agents are avoided in favor of insulin due to concerns regarding placental transfer and long-term fetal effects. Insulin remains the superior choice because it allows for flexible dosing that can be adjusted as insulin resistance increases throughout gestation.